Velvetbean (Mucuna pruriens) plants impede the growth of neighboring plants. One compound, 3-(3',4'-dihydroxyphenyl)-L-alanine (L-DOPA), is responsible for the allelopathic capacity of velvetbean. This compound is an active allelochemical that decreases root growth of several plant species. In mammals, L-DOPA is a well-known therapeutic agent for the symptomatic relief of Parkinson's disease. However, its mode of action in plants is still not well understood. To address such issues, gene expression in Arabidopsis thaliana plants, which had been exposed to L-DOPA, was analyzed using DNA microarrays. After 6 h of L-DOPA exposure, the expression of 110 genes was significantly upregulated, and the expression of 69 genes was significantly downregulated. These induced genes can be divided into different functional categories, mainly on the basis of subcellular localization, metabolism, and proteins with a binding function or cofactor requirement. Based on these results, we suggest that L-DOPA acts by two mechanisms: it influences amino acid metabolism and deregulates metal homeostasis, especially that of iron, which is required for the fundamental biological processes of all organisms.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00425-010-1294-7DOI Listing

Publication Analysis

Top Keywords

l-dopa
6
plants
5
microarray analysis
4
analysis arabidopsis
4
arabidopsis plants
4
plants response
4
response allelochemical
4
allelochemical l-dopa
4
l-dopa velvetbean
4
velvetbean mucuna
4

Similar Publications

This study is to produce biogenic silver nanoparticles (AgNPs) by utilizing aqueous extracts derived from Turnera Sublata (TS) leaves under visible light. Subsequently, these nanoparticles are coated with eosin-yellow (EY) to enhance sensitivity and selectivity in L-3,4-dihydroxyphenylalanine (L-dopa) detection. This method encompasses the deposition of metal onto the Ag NPs, resulting in the formation of EY-AgNPs.

View Article and Find Full Text PDF

Predictors of drooling severity in people with Parkinson's disease.

J Neurol

January 2025

Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal.

Background: Drooling, defined as the unintentional loss of saliva from the anterior oral cavity, remains poorly understood in terms of the underlying clinical factors in people with Parkinson's disease (PwP). This study aims to clarify these factors by analyzing predictors and secondarily the correlates with the severity of drooling in PwP.

Methods: We conducted a cross-sectional study involving 42 PwP with drooling and 59 without drooling.

View Article and Find Full Text PDF

Bioinspired coatings that mimic the adhesive properties of mussels have received considerable attention for surface modification applications. While polydopamine chemistry has been widely used to develop functional coatings, 3,4-dihydroxyphenyl-l-alanine (l-DOPA), a key component of mussel adhesive proteins, has received less attention because, compared to dopamine, it is relatively difficult to form effective coatings on solid substrates in mildly alkaline solutions. Although several methods have been explored to improve the efficiency of l-DOPA coatings, there is still a need to expand the l-DOPA-based surface chemistry.

View Article and Find Full Text PDF

Fluctuation-related pain (FRP) affects more than one third of people with Parkinson's disease (PwP, PD) and has a harmful effect on health-related quality of life (HRQoL), but often remains under-reported by patients and neglected by clinicians. The National Institute for Health and Care Excellence (NICE) recommends The Parkinson KinetiGraphTM (the PKGTM) for remote monitoring of motor symptoms. We investigated potential links between the PKGTM-obtained parameters and clinical rating scores for FRP in PwP in an exploratory, cross-sectional analysis of two prospective studies: "The Non-motor International Longitudinal, Real-Life Study in PD-NILS" and "An observational-based registry of baseline PKG™ in PD-PKGReg".

View Article and Find Full Text PDF

Oxidation of dopamine can cause various side effects, which ultimately leads to cell death and contributes to Parkinson's disease (PD). To counteract dopamine oxidation, newly synthesized dopamine is quickly transported into vesicles via vesicular monoamine transporter 2 (VMAT2) for storage. VMAT2 expression is reduced in patients with PD, and studies have shown increased accumulation of dopamine oxidation byproducts and α-synuclein in animals with low VMAT2 expression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!